☆ 4.6 Article

Risk Factors for Bleeding in Cancer Patients Treated with Conventional Dose Followed by Low-Dose Apixaban for Venous Thromboembolism

THROMBOSIS AND HAEMOSTASIS (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Risk factors for recurrence and major bleeding in patients with cancer-associated venous thromboembolism

Maria Cristina Vedovati et al.

Summary: Patients with cancer-associated venous thromboembolism (VTE) face high risks of recurrence and treatment-emergent bleeding, but factors associated with these risks are not well-defined. This study analyzed patients included in the Caravaggio study to identify risk factors for recurrent VTE and major bleeding in cancer-associated VTE. Independent risk factors for recurrent VTE included deep vein thrombosis as the initial event, ECOG status of 1 or more, pancreatic or hepatobiliary cancer site, concomitant anti-cancer treatment, and creatinine clearance. Independent risk factors for major bleeding included ECOG status of 2, genitourinary or upper gastrointestinal cancer site, and non-resected luminal gastrointestinal cancer. Understanding these predictors can help optimize anticoagulant treatment in cancer-associated VTE patients.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2023)

Add to Collection

Article Hematology

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up

Trine-Lise Larsen et al.

Summary: For cancer patients, reducing the dosage of apixaban to 2.5 mg twice daily after 6 months of full-dose treatment seems to be safe, and the incidence rate of recurrent VTE and major bleeding remains low thereafter.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Review Medicine, General & Internal

Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis

Irbaz Bin Riaz et al.

Summary: Direct oral anticoagulants (DOACs) are more effective and safe than low-molecular-weight heparin in the treatment of cancer-associated thrombosis (CAT) in adults. Apixaban and rivaroxaban are more effective than dalteparin in reducing recurrent venous thromboembolism (VTE) events. Edoxaban has a higher risk of major bleeding compared to dalteparin, while rivaroxaban has a higher risk of clinically relevant nonmajor bleeding compared to dalteparin and other DOACs. There are no significant differences between DOACs in terms of VTE recurrences and major bleeding.

MAYO CLINIC PROCEEDINGS (2022)

Add to Collection

Article Hematology

Estimating Bleeding Risk in Patients with Cancer-Associated Thrombosis: Evaluation of Existing Risk Scores and Development of a New Risk Score

Maria A. de Winter et al.

Summary: The study compared different methods of estimating clinically relevant bleeding risk in patients with CAT, finding that existing risk scores performed poorly while a pragmatic classification based on cancer type provided slightly better estimates. Further improvement may be possible with a new prediction model, but external validation is needed.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer

Giancarlo Agnelli et al.

Summary: The efficacy and safety of anticoagulant treatment for VTE may vary in patients with different cancer sites. Oral apixaban is considered a valid alternative to subcutaneous dalteparin for the treatment of cancer-associated VTE, with no significant differences in recurrence rates or major bleeding observed across different cancer types.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Bleeding with Apixaban and Dalteparin in Patients with Cancer-Associated Venous Thromboembolism: Results from the Caravaggio Study

Walter Ageno et al.

Summary: The Caravaggio study showed that apixaban is a safe alternative to LMWH for the treatment of CAT patients, without an increased risk of gastrointestinal bleeding.

THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

Risk factors for gastrointestinal bleeding in patients with gastrointestinal cancer using edoxaban

Floris T. M. Bosch et al.

Summary: In gastrointestinal cancer patients receiving edoxaban, advanced cancer and low hemoglobin levels were significantly associated with an increased risk of gastrointestinal bleeding. However, further research is needed to identify other risk factors.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

Influence of body mass index on clinical outcomes in venous thromboembolism: Insights from GARFIELD-VTE

Jeffrey Weitz et al.

Summary: The risk of mortality is lower in obese VTE patients compared to patients with a normal BMI, while underweight VTE patients have the highest risk of mortality and major bleeding.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Medicine, General & Internal

Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism

Damon E. Houghton et al.

Summary: The study compared bleeding risk in patients with GI cancer and non-GI cancer receiving anticoagulation for acute Ca-VTE, finding that there was no significant difference in major bleeding or CRNMB between the two groups. Apixaban had a higher rate of major bleeding in patients with luminal GI cancer compared to non-GI cancer and to enoxaparin in luminal GI cancer patients, while rivaroxaban showed no increased risk of major bleeding in GI cancer patients.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Hematology

Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial

Robert D. McBane et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Review Hematology

Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis

Frits Mulder et al.

BLOOD (2020)

Add to Collection

Review Hematology

Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis

Michela Giustozzi et al.

THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Medicine, General & Internal

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

Giancarlo Agnelli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Hematology

Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism

Trine-Lise Hannevik et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome

Nuria Vicente-Ibarra et al.

EUROPEAN JOURNAL OF INTERNAL MEDICINE (2019)

Add to Collection

Article Oncology

Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

Annie M. Young et al.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Gary E. Raskob et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Hematology

Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study

Frederikus A. Klok et al.

BRITISH JOURNAL OF HAEMATOLOGY (2018)

Add to Collection

Article Hematology

Clinical Impact of Bleeding in Cancer-Associated Venous Thromboembolism: Results from the Hokusai VTE Cancer Study

Noemie Kraaijpoel et al.

THROMBOSIS AND HAEMOSTASIS (2018)

Add to Collection

Article Hematology

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

S. Kaatz et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)

Add to Collection

Article Medicine, General & Internal

Long-Term Survival in a Large Cohort of Patients with Venous Thrombosis: Incidence and Predictors

Linda E. Flinterman et al.

PLOS MEDICINE (2012)

Add to Collection

Article Critical Care Medicine

A Novel User-Friendly Score (HAS-BLED) To Assess 1-Year Risk of Major Bleeding in Patients With Atrial Fibrillation The Euro Head Survey

Ron Pisters et al.

CHEST (2010)

Add to Collection

Article Hematology

Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism.: Findings from the RIETE Registry

Nuria Ruiz-Gimenez et al.

THROMBOSIS AND HAEMOSTASIS (2008)

Add to Collection

Article Hematology

Cancer and thrombosis: from molecular mechanisms to clinical presentations

H. R. Buller et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)

Add to Collection

Article Hematology

Incidence and mortality of venous thrombosis:: a population-based study

I. A. Naess et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)

Add to Collection

Article Hematology

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

S Schulman et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)

Add to Collection

Article Medicine, General & Internal

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

JW Blom et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)

Add to Collection

Article Medicine, General & Internal

Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation

MC Fang et al.

ANNALS OF INTERNAL MEDICINE (2004)

Add to Collection

Article Oncology

Mucosal damage: A major risk factor for severe complications after cytotoxic therapy

DE Peterson et al.

SEMINARS IN ONCOLOGY (2004)

Add to Collection

Article Hematology

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis

P Prandoni et al.

BLOOD (2002)

Add to Collection

Article Medicine, General & Internal

Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study

JA Heit et al.

ARCHIVES OF INTERNAL MEDICINE (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.